Attovia registers Phase 1 trial of ATTO-1091 for ulcerative colitisSep 15Trial updateATTO-1091Attovia Therapeutics Inc
Attovia reports ATTO-1310 pruritus proof of concept, plans Phase 2 for 2027Sep 2Quarterly updateATTO-1310Attovia Therapeutics Inc
Attovia Therapeutics prices $289 million IPO ahead of Nasdaq debutAug 5FinancingAttovia Therapeutics Inc
Attovia Therapeutics files S-1 for IPO on Nasdaq under ticker ATTOJul 14FinancingAttovia Therapeutics Inc
Sign inSign in